Zacks Investment Research upgraded shares of Tekmira Pharmaceuticals (TKMR) from N/A to OUTPERFORM on March 20, 2013, with a target price of $12.00.
Tekmira is a development stage biotech company. We are optimistic about the great potential of the Company's LNP delivery technology, which enables the systemic delivery of RNAi drug candidates. Tekmira has built a diversified pipeline which targets multiple indications including cancer and infection. Lead drug candidate TKM-PLK1 will enter into a Phase II clinical trial in 2013. Government sponsored TKM-Ebola is under accelerated "Animal Rule" development. Partnerships should build shareholder value in a rapid and cost-effective way. We rate the Company's shares Outperform.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on Tekmira Pharmaceuticals (TKMR),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment